
Anne Cambon-Thomsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1817650/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
2	Whole-genome sequencing in health care. European Journal of Human Genetics, 2013, 21, 580-584.	1.4	330
3	Prepublication data sharing. Nature, 2009, 461, 168-170.	13.7	243
4	Systems medicine and integrated care to combat chronic noncommunicable diseases. Genome Medicine, 2011, 3, 43.	3.6	181
5	Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nature Communications, 2014, 5, 5135.	5.8	158
6	Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. Journal of Allergy and Clinical Immunology, 2017, 139, 388-399.	1.5	145
7	Towards a European consensus for reporting incidental findings during clinical NGS testing. European Journal of Human Genetics, 2015, 23, 1601-1606.	1.4	85
8	Comprehensive catalog of European biobanks. Nature Biotechnology, 2011, 29, 795-797.	9.4	83
9	Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. European Journal of Human Genetics, 2011, 19, S6-S44.	1.4	75
10	Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: A Mechanisms of the Development of Allergy (MeDALL) Seminar. Journal of Allergy and Clinical Immunology, 2012, 129, 943-954.e4.	1.5	68
11	The role of a bioresource research impact factor as an incentive to share human bioresources. Nature Genetics, 2011, 43, 503-504.	9.4	66
12	Developing a policy for paediatric biobanks: principles for good practice. European Journal of Human Genetics, 2013, 21, 2-7.	1.4	63
13	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. Current Pharmaceutical Design, 2014, 20, 5928-5944.	0.9	63
14	Mapping the translational science policy â€~valley of death'. Clinical and Translational Medicine, 2013, 2, 14.	1.7	58
15	Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analyses. Immunogenetics, 2010, 62, 729-740.	1.2	52
16	Including all voices in international data-sharing governance. Human Genomics, 2018, 12, 13.	1.4	50
17	Guidelines for reporting secondary findings of genome sequencing in cancer genes: the SFMPP recommendations. European Journal of Human Genetics, 2018, 26, 1732-1742.	1.4	44
18	Developing a guideline to standardize the citation of bioresources in journal articles (CoBRA). BMC Medicine, 2015, 13, 33.	2.3	43

#	Article	IF	CITATIONS
19	Italian appeal court: a genetic predisposition to commit murder?. European Journal of Human Genetics, 2010, 18, 519-521.	1.4	39
20	ELSI 2.0 for Genomics and Society. Science, 2012, 336, 673-674.	6.0	39
21	Quantifying the use of bioresources for promoting their sharing in scientific research. GigaScience, 2013, 2, 7.	3.3	38
22	Practical guidelines addressing ethical issues pertaining to the curation of human locus-specific variation databases (LSDBs). Human Mutation, 2010, 31, 1179-1184.	1.1	36
23	Measuring the Contribution of Tumor Biobanks to Research in Oncology: Surrogate Indicators and Bibliographic Output. Biopreservation and Biobanking, 2013, 11, 235-244.	0.5	29
24	Beyond public health genomics: proposals from an international working group. European Journal of Public Health, 2014, 24, 877-879.	0.1	22
25	Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort. Arthritis Care and Research, 2012, 64, 872-880.	1.5	20
26	FAIRness Literacy: The Achilles' Heel of Applying FAIR Principles. Data Science Journal, 2020, 19, .	0.6	19
27	Communication of results and disclosure of incidental findings in longitudinal paediatric research. Pediatric Allergy and Immunology, 2013, 24, 389-394.	1.1	17
28	Association of IL-2RA and IL-2RB genes with erosive status in early rheumatoid arthritis patients (ESPOIR and RMP cohorts). Joint Bone Spine, 2014, 81, 228-234.	0.8	17
29	How to responsibly acknowledge research work in the era of big data and biobanks: ethical aspects of the Bioresource Research Impact Factor (BRIF). Journal of Community Genetics, 2018, 9, 169-176.	0.5	15
30	Open Data Sharing in the Context of Bioresources. Acta Informatica Medica, 2013, 21, 291.	0.5	15
31	The Emergence of Biobanks in the Legal Landscape: Towards a New Model of Governance. Journal of Law and Society, 2012, 39, 113-130.	0.4	14
32	Genomic Incidental Findings: Reducing the Burden to Be Fair. American Journal of Bioethics, 2013, 13, 52-54.	0.5	13
33	International transfers of personal data for health research following Schrems II: a problem in need of a solution. European Journal of Human Genetics, 2021, 29, 1502-1509.	1.4	12
34	Biobankers: Treat the Poison of Invisibility with CoBRA, a Systematic Way of Citing Bioresources in Journal Articles. Biopreservation and Biobanking, 2016, 14, 350-352.	0.5	11
35	Fostering global data sharing: highlighting the recommendations of the Research Data Alliance COVID-19 working group. Wellcome Open Research, 2020, 5, 267.	0.9	11
36	The impact of European embryonic stem cell patent decisions on research strategies. Nature Biotechnology, 2015, 33, 41-43.	9.4	10

#	Article	IF	CITATIONS
37	Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic- and tumor-related biomarkers for response and toxicity. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 529.e9-529.e16.	0.8	9
38	Direct-to-consumer health genetic testing services: What commercial strategies for which socio-ethical issues?. Health Sociology Review, 2013, 22, 75-87.	1.7	8
39	A new classification of HLA-DRB1 alleles based on acid–base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIR and EAC cohort). RMD Open, 2015, 1, e000099.	1.8	8
40	Disclosing Results to Genomic Research Participants: Differences That Matter. American Journal of Bioethics, 2012, 12, 20-22.	0.5	7
41	Patients' motives for consenting or refusing to participate in a clinical trial in organ transplantation. Clinical Transplantation, 2013, 27, 724-731.	0.8	7
42	ls it research or is it clinical? Revisiting an old frontier through the lens of next-generation sequencing technologies. European Journal of Medical Genetics, 2018, 61, 634-641.	0.7	7
43	Towards new tools for bioresource use andÂsharing. Information Services and Use, 2017, 36, 133-146.	0.1	6
44	Fostering global data sharing: highlighting the recommendations of the Research Data Alliance COVID-19 working group. Wellcome Open Research, 2020, 5, 267.	0.9	6
45	Critical points for an accurate human genome analysis. Human Mutation, 2017, 38, 912-921.	1.1	5
46	Governing Biobanks Through a European Infrastructure. The International Library of Ethics, Law and Technology, 2015, , 139-151.	0.2	5
47	From the arcane to the mundane: engaging French publics in discussing clinical applications of genomic technology. New Genetics and Society, 2016, 35, 1-28.	0.7	4
48	Quand l'anticipation devient plurielleÂ: la complexité des données génomiques à l'épreuve des p professionnelles. Revue Francaise D'Ethique Appliquee, 2016, Nº 2, 19-28.	oratiques 0.0	4
49	Professionals' Attitudes Regarding Large-Scale Genetic Information Generated Through Next Generation Sequencing in Research. Journal of Empirical Research on Human Research Ethics, 2014, 9, 56-58.	0.6	2
50	Judging health risk as a function of risk factors and type of illness: Do people weight risk factors in a flexible way?. Journal of Health Psychology, 2016, 21, 832-843.	1.3	2
51	Genetic markers as a predictive tool based on statistics in medical practice: ethical considerations through the analysis of the use of HLA-B*27 in rheumatology in France. Frontiers in Genetics, 2015, 6, 299.	1.1	1
52	Genome Editing and Dialogic Responsibility: "What's in a Name?― American Journal of Bioethics, 2015, 15, 54-57.	0.5	1
53	Attitudes of French populations towards the disclosure of unsolicited findings in medical genetics. Journal of Health Psychology, 2019, 26, 135910531988662.	1.3	1
54	International Transfers of Health Research Data Following Schrems II: A Problem in Need of a Solution. SSRN Electronic Journal, 0, , .	0.4	1

#	Article	IF	CITATIONS
55	French People's Views on the Appropriateness of Disclosing an Unsolicited Finding in Medical Genetics: A Preliminary Study. Universitas Psychologica, 2018, 17, 1-11.	0.6	1
56	Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib. Cancers, 2022, 14, 2838.	1.7	1
57	2004–2009Â: révision de la loi de bioéthique en France, quels enjeux, quels débatsÂ? Assistance médio la procréation, gestation pour autrui, transplantation. Medecine Et Droit, 2010, 2010, 42-48.	cale Ã 0.1	Ο
58	Clarity and claims in variation/mutation databasing. Nature Biotechnology, 2011, 29, 790-792.	9.4	0
59	BRIF Workshop Introduction. Nature Precedings, 2011, , .	0.1	Ο
60	The BRIF (Bioresource Research Impact Factor) as a tool for improving bioresource sharing in biomedical research. Nature Precedings, 2011, , .	0.1	0
61	Producing â€~Human Elements Based Medical Technologies' in Biotech Companies: Some Ethical and Organisational Ingredients for Innovative Cooking. Science, Technology and Society, 2013, 18, 93-114.	1.1	Ο
62	Academic Valorization of Biobanks. , 2018, , 113-125.		0